Ms. Anne Whitaker
Ms. Anne Whitaker was appointed as a non-executive director of ICON plc in July 2024.
Ms. Whitaker is an experienced healthcare executive, advisor and director. Ms. Whitaker currently serves as managing partner of Anne Whitaker Group, LLC, a board and private equity advisory firm and as an Operating Partner of NewVale Capital, a Private Equity firm. Ms. Whitaker was previously CEO and Chair of Aerami Therapeutics, CEO and Director of Novoclem Therapeutics and earlier in her career, Ms. Whitaker held senior executive leadership positions at Bausch Health, Sanofi, GlaxoSmithKline, and multiple CEO roles for private and public development-stage companies.
Ms. Whitaker serves as the Chair of QurAlis and as a non-executive director of Nykode Therapeutics, Trinity Life Sciences, Byrn Pharma, Bespak, and is a Member of the Board of Trustees of the University of North Alabama. She previously served on the boards of Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Cree, Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group and Synta Pharmaceuticals.
Ms. Whitaker holds a BSc in Chemistry and Business from the University of North Alabama.